Dexcom (NSDQ:DXCM) announced today that it received FDA clearance for its Dexcom Partner Web application programming interfaces (APIs).
The San Diego-based company’s Dexcom Partner Web APIs enable invited third-party developers to integrate real-time continuous glucose monitoring (CGM) data into their digital health apps and devices.
Get the full story at our sister site, Drug Delivery Business News.
Dexcom (NSDQ:DXCM) today shared results from two studies of continuous glucose monitors, including its next-generation G7 CGM.
San Diego-based Dexcom presented the studies during the 14th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD).
Get the full story at our sister site, Drug Delivery Business News.
Kaiser Permanente touts a study demonstrating that using continuous glucose monitors offers better blood sugar control for patients with type 2 diabetes.
Patients with insulin-treated type 2 diabetes using continuous glucose monitors (CGMs) typically had better blood sugar control and fewer visits to the emergency room for hypoglycemia, the study found. The study was published yesterday in JAMA and was supported by an independent investigator award from Dexcom and funding from the National Institute of Diabetes and Digestive and Kidney Diseases.
Get the full story at our sister site, Drug Delivery Business News.
Barclays analysis projects that medtech might be on its way to a stretch of “outperformance” even in the wake of the COVID-19 pandemic.
According to SeekingAlpha, the report cited eight reasons that make the investment bank bullish on the industry in the coming years, starting with what it calls “robust innovation.”
On top of the evolving innovation in medtech, Barclays expects the canceled procedures of 2020 (as a result of COVID-19) to return, while new technology could increase diagnoses.
Direct-to-consumer advertising, a potential return to “normality” in a post-pandemic scape, surveys indicating a resurgence in elective surgeries, healthy balance sheets and an aging population as a tailwind round out the reasons why Barclays expects success for medtech over the next several years.
Medtech companies that Barclays stands “overweight on” include Abbott (26.72% upside), Boston Scientific (18.55% ups…
Eli Lilly (NYSE:LLY) today announced deals with four companies whose diabetes management tech will work with on Lilly’s latest insulin pen.
The Tempo Pen is a modified version of Lilly’s existing prefilled, disposable insulin pen to which the Tempo Smart Button — in late-stage development – attaches. Through these new agreements, the Tempo Smart Button will pair with software and/or medical devices offered by Dexcom (NSDQ:DXCM), Glooko, myDiabby Healthcare (Bordeaux, France) and Roche, with its mySugr app, to facilitate the integration of personalized data and actionable insights.
Get the full story on our sister site, Drug Delivery Business News.
After back-to-back all-time best performances, the medtech industry had a slight regression over the course of the last week.
MassDevice‘s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — had been continuously ticking up since the beginning of April, with its mark of 112.25 on April 16 representing an all-time best, topping the previous high of 110.96 set on Feb. 15.
Just one week later, the index topped itself again, reaching 114.58 to end the week on April 23, marking an increase of 2.1% from the previous week. However, things have settled down and the industry responded in kind, dipping -1.6% to 112.7 to end last week (April 30).
In spite of the slight decrease over the past week, the industry continues to reflect a bounceback from the struggles brought on by the COVID-19 pandemic.
Overall, has produced a 22.1% rise from the pre-pandemic high of 92.32 (set on Feb. 19, 2020), plus an 81.4% increase from…
Dexcom (NSDQ:DXCM) shares took a hit after hours today despite first-quarter results that beat the consensus forecast.
DXCM shares were down -5.2% at $400 per share after hours. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — was down -0.8%.
Get the full story at our sister site, Drug Delivery Business News.
Welldoc announced today that it will offer its BlueStar digital health solution with Dexcom’s G6 CGM system as a single platform.
Columbia, Md.-based Welldoc’s FDA-cleared BlueStar system offers guidance to individuals through the self-management of diabetes, while Dexcom’s G6 continuous glucose monitoring (CGM) system measures glucose levels just beneath the skin’s surface and wirelessly transmits data every five minutes.
Get the full story at our sister site, Drug Delivery Business News.
While medtech’s performance still isn’t mirroring the beginning of 2021, the industry is showing signs of life with a small improvement last week.
The year’s strong start, during which MassDevice‘s MedTech 100 index notched an all-time best of 110.96 points (Feb. 15) came to an end later that month and carried over into March, with the index hitting its lowest recent point on March 8 (102.16), marking a fall at a level not seen since October.
Even after a slight rise earlier this month, the index struggled again two weeks ago with another small dip. However, after coming in at 104.05 on March 19, the index got a slight boost over the past week, finishing at 104.87 on March 26, representing a 0.8% rise.
Despite the up-and-down nature of the past couple of months, the index represents a much better situation for the industry compared to this time a year ago when the COVID-19 pandemic was in full swing. The index is up 13.6% from its pre-p…
The latest standard of broadband technology continues to make waves in 2021. But what about medtech?
Cellphone using 5G
Cellphone using 5G (Imagy by Frederik Lipfert on Unsplash)
Wireless tech companies such as Qualcomm are predicting download speeds as high as 10 gigabits per second as next-generation 5G cellular networks roll out worldwide.
The open question in medtech is how quickly companies will take advantage of the super-speedy connectivity for their own products.
“5G is about bringing more capacity and speed to the pipes,” said Don Jones, a member of the advisory council at BrightInsight and a veteran of the digital healthcare space. Jones spent more than 11 years building Qualcomm’s healthcare group.
“What you have to analyze is, ‘Can healthcare take advantage of what essentially amounts to these bigger pipes?’ Because more data can be shoved through them with m…
Dexcom (NASDAQ: DXCM) announced today that it has promoted Jereme Sylvain to become a new EVP and CFO at the continuous glucose monitoring company.
Sylvain — who joined Dexcom in 2018 and was most recently SVP of finance and chief accounting officer — will report to COO Quentin Blackford.
Previously, Blackford had been serving as both COO and CFO of the San Diego–based company.
Get the full story on our sister site Drug Delivery Business News.
Insulet CEO Shacey Petrovic shares vision for OmniPod insulin delivery.
Medtech start ups developing continuous glucose monitors have caught the eye of at least one potential – and powerful – partner – Insulet Corp.
In an interview with the DeviceTalks Weekly Podcast, CEO Shacey Petrovic said the maker of the OmniPod insulin-delivery device sees partnering with other companies as the likely path to creating a single device capable of reading glucose levels and delivering insulin. Insulet last year announced partnerships with DexCom and Abbott.
“There are some really interesting technologies on the horizon,” Petrovic said. “There might be 40 early-stage CGMs in development so we’ll see how the market plays out. But we couldn’t be more delighted with our partnerships with Abbott and Dexcom.”
The partnerships give Insulet access to technology that’s able to measure glucose levels in…